KURA News and Press, Kura Oncology Inc. From 12/10/18

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...

Shares of Kura Oncology ( KURA ) have risen by only 17% since my initial article highlighted early clinical results for lead drug candidate tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC). The stock has lost nearly 40% sinc...

– Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL – – AITL and other PTCL patients with high CXCL12 expression experienced 50% ORR and 90% clinical benefit with tipifarnib after median of three prior therapies &#x...

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled...

Kura Oncology, Inc. (KURA) Q3 2018 Earnings Conference Call November 5, 2018 4:30 p.m. ET Executives Pete De Spain - VP, IR and Corporate Communications Troy Wilson - President and CEO Marc Grasso - CFO and Chief Business Officer Antonio Gualberto - Head, Development and Chief ...

Kura Oncology (NASDAQ: KURA ): Q3 GAAP EPS of -$0.40 beats by $0.01. More news on: Kura Oncology, Earnings news and commentary, Healthcare stocks news, Read more ...

– Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway – – Encouraging preliminary clinical activity observed in HRAS mutant SCC cohort – – Preliminary data from AITL and CXCL12+ cohorts in Phase 2 trial of tipifarnib in PTCL upc...

– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...

SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that two abstracts related to the company’s lead product candidate, tipifarnib, ...

SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2018 financial results after the close of U.S. financ...